eComment. A novel lower age threshold for use of biological valves.

valve-in-valve implantation for the treatment of stentless aortic valve dysfunction. J Thorac Cardiovasc Surg 2010;140:246–8. [11] Ferrari E, Marcucci C, Sulzer C, von Segesser LK. Which available transapical transcatheter valve fits into degenerated aortic bioprostheses? Interact CardioVasc Thorac Surg 2010;11:83–5. [12] Ye J, Webb JG, Cheung A, Soon JL, Wood D, Thompson CR et al. Transapical transcatheter aortic valve-in-valve implantation: Clinical and hemodynamic outcomes beyond 2 years. Thorac Cardiovasc Surg. 2012 [Epub ahead of print]. [13] Badhwar V, Ofenloch JC, Rovin JD, van Gelder HM, Jacobs JP. Noninferiority of closely monitored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients. Ann Thorac Surg 2012;93:748–53. [14] Al-Khaja N, Belboul A, Rashid M, El-Gatit A, Roberts D, Larsson S et al. The influence of age on the durability of Carpentier–Edwards biological valves. Thirteen years follow-up. Eur J Cardiothorac Surg 1991;5:635–40. [15] David TE, Armstrong S, Maganti M. Hancock II bioprosthesis for aortic valve replacement: the gold standard of bioprosthetic valves durability? Ann Thorac Surg 2010;90:775–81. [16] Jaussaud N, Gariboldi V, Giorgi R, Grisoli D, Chalvignac V, Thuny F et al. Risk of reoperation for aortic bioprosthesis dysfunction. J Heart Valve Dis 2009;18:256–61.